Research presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference highlighted the efficacy of the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv in detecting hepatocellular carcinoma (HCC). The pilot study involving 36 patients demonstrated a sensitivity of 91.7% for HCC detection, including tumors smaller than one centimeter. This tracer is noted for its ability to provide clearer images and potentially facilitate earlier diagnoses, leading to improved treatment outcomes and survival rates for patients. Additionally, the conference showcased various other studies, including one on the dual-targeted 177Lu-DOTA-FAPI-RGD, which showed promising results in inhibiting cancer growth in advanced adenocarcinomas. Another meta-analysis indicated that while (68Ga)Ga-PSMA-11 offers high sensitivity for prostate cancer detection, (18F)-based radiotracers may enhance imaging flexibility. Other notable findings included a study suggesting that mid-treatment MRI could predict chemotherapy responses in breast cancer patients and research highlighting higher allostatic loads linked to increased breast cancer incidence in minority women.
Mon, 23 Jun 2025 20:59:50 GMT | diagnosticimaging.com